Information  X 
Enter a valid email address

Tissue Regenix Group (TRX)


Thursday 18 March, 2021

Tissue Regenix Group

Initial phase of US facility expansion complete

RNS Number : 6080S
Tissue Regenix Group PLC
18 March 2021



Tissue Regenix Group plc

("Tissue Regenix" or "the Group")


Initial phase of new US facility expansion complete

Increase of the Company's manufacturing footprint in 21,000 sq. ft facility


Leeds, 18 March 2021 - Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces the completion of the initial phase of its expansion plan at the Company's San Antonio Texas facility. As previously disclosed, the Company had secured a ten-year lease on a 21,000 sq. ft facility adjacent to its existing facility to address manufacturing capacity constraints.


The initial part of Phase one of the expansion project, which has now been completed, comprised of relocating facilities designated for distribution and frozen tissue storage, both of which had outgrown their existing space in the San Antonio facility. The new freezer facility triples the Company's current storage capacity allowing Tissue Regenix to hold more donor tissue onsite. The new distribution area enables the Company to integrate distribution and finished goods into a more efficient operating space.


Work has also started on the development of two additional clean rooms at the existing San Antonio facility, which will bring the total number of clean rooms to seven, as well as the expansion space for supporting departments.  These developments, which will complete Phase one of the expansion project, are scheduled for completion during H1 2021.


Daniel Lee, Chief Executive Officer, of Tissue Regenix Group plc said: " The addition of our new facility, adjacent to our original site, is welcome as it provides the Group the opportunity to grow with added flexibility. Our choice to do this in phases was advantageous by enabling us to be efficient with our capital and plan our expansion in line with the challenges our industry has faced with the COVID-19 pandemic. We are confident that demand exists to justify these capacity expansions and are looking forward to updating shareholders as the expansion project progresses."


For more Information:


Tissue Regenix Group plc

David Cocke, Chief Financial Officer

Via Walbrook PR

Stifel Nicolaus Europe Limited (Nominated Adviser and Broker)

Ben Maddison / Alex Price

Tel:  +44(0)20 7710 7600




Walbrook PR Ltd

Alice Woodings / Lianne Cawthorne / Paul McManus

Tel: +44 (0)20 7933 8780

[email protected]


About Tissue Regenix ( )

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.


In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.



This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

a d v e r t i s e m e n t